Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers

Melanie Machiels; Redouane Oulkadi; Trine Tramm; Shane R. Stecklein; Navita Somaiah; Alex De Caluwé; Jonathan Klein; William T. Tran; Roberto Salgado

doi:10.1016/j.breast.2023.06.010

Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers

Melanie Machiels, Redouane Oulkadi, Trine Tramm, Shane R. Stecklein, Navita Somaiah, Alex De Caluwé, Jonathan Klein, William T. Tran, Roberto Salgado

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to de-escalate or omit RT based on clinicopathologic features have been successful, there remain substantial opportunities to refine individualised RT based on tumour biology. A major area of clinical and research interest is to ascertain the individualised risk of loco-regional recurrence to direct treatment decisions regarding escalation and de-escalation of RT. Patient-tailored treatment with RT is considerably lagging behind compared with the massive progress made in the field of personalised medicine that currently mainly applies to decisions on the use of systemic therapy or targeted agents. Herein we review select literature surrounding the use of tumour genomic biomarkers and biomarkers of the immune system, including tumour infiltrating lymphocytes (TILs), within the management of breast cancer, specifically as they relate to progress in moving toward analytically validated and clinically tested biomarkers utilized in RT.

Original language	English (US)
Pages (from-to)	13-21
Number of pages	9
Journal	Breast
Volume	71
DOIs	https://doi.org/10.1016/j.breast.2023.06.010
State	Published - Oct 2023
Externally published	Yes

Keywords

Biomarkers
Breast cancer
Gene expression profile
Genomically adjusted radiation dose
Personalised radiation therapy
Radiation therapy
Response guided therapy
Tumour infiltrating lymphocytes

ASJC Scopus subject areas

Surgery
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.breast.2023.06.010

Cite this

@article{1c349598a371457aa4a8797f213c3808,

title = "Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers",

abstract = "Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to de-escalate or omit RT based on clinicopathologic features have been successful, there remain substantial opportunities to refine individualised RT based on tumour biology. A major area of clinical and research interest is to ascertain the individualised risk of loco-regional recurrence to direct treatment decisions regarding escalation and de-escalation of RT. Patient-tailored treatment with RT is considerably lagging behind compared with the massive progress made in the field of personalised medicine that currently mainly applies to decisions on the use of systemic therapy or targeted agents. Herein we review select literature surrounding the use of tumour genomic biomarkers and biomarkers of the immune system, including tumour infiltrating lymphocytes (TILs), within the management of breast cancer, specifically as they relate to progress in moving toward analytically validated and clinically tested biomarkers utilized in RT.",

keywords = "Biomarkers, Breast cancer, Gene expression profile, Genomically adjusted radiation dose, Personalised radiation therapy, Radiation therapy, Response guided therapy, Tumour infiltrating lymphocytes",

author = "Melanie Machiels and Redouane Oulkadi and Trine Tramm and Stecklein, {Shane R.} and Navita Somaiah and {De Caluw{\'e}}, Alex and Jonathan Klein and Tran, {William T.} and Roberto Salgado",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = oct,

doi = "10.1016/j.breast.2023.06.010",

language = "English (US)",

volume = "71",

pages = "13--21",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers

AU - Machiels, Melanie

AU - Oulkadi, Redouane

AU - Tramm, Trine

AU - Stecklein, Shane R.

AU - Somaiah, Navita

AU - De Caluwé, Alex

AU - Klein, Jonathan

AU - Tran, William T.

AU - Salgado, Roberto

PY - 2023/10

Y1 - 2023/10

N2 - Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to de-escalate or omit RT based on clinicopathologic features have been successful, there remain substantial opportunities to refine individualised RT based on tumour biology. A major area of clinical and research interest is to ascertain the individualised risk of loco-regional recurrence to direct treatment decisions regarding escalation and de-escalation of RT. Patient-tailored treatment with RT is considerably lagging behind compared with the massive progress made in the field of personalised medicine that currently mainly applies to decisions on the use of systemic therapy or targeted agents. Herein we review select literature surrounding the use of tumour genomic biomarkers and biomarkers of the immune system, including tumour infiltrating lymphocytes (TILs), within the management of breast cancer, specifically as they relate to progress in moving toward analytically validated and clinically tested biomarkers utilized in RT.

AB - Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to de-escalate or omit RT based on clinicopathologic features have been successful, there remain substantial opportunities to refine individualised RT based on tumour biology. A major area of clinical and research interest is to ascertain the individualised risk of loco-regional recurrence to direct treatment decisions regarding escalation and de-escalation of RT. Patient-tailored treatment with RT is considerably lagging behind compared with the massive progress made in the field of personalised medicine that currently mainly applies to decisions on the use of systemic therapy or targeted agents. Herein we review select literature surrounding the use of tumour genomic biomarkers and biomarkers of the immune system, including tumour infiltrating lymphocytes (TILs), within the management of breast cancer, specifically as they relate to progress in moving toward analytically validated and clinically tested biomarkers utilized in RT.

KW - Biomarkers

KW - Breast cancer

KW - Gene expression profile

KW - Genomically adjusted radiation dose

KW - Personalised radiation therapy

KW - Radiation therapy

KW - Response guided therapy

KW - Tumour infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85164406721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164406721&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2023.06.010

DO - 10.1016/j.breast.2023.06.010

M3 - Review article

C2 - 37437386

AN - SCOPUS:85164406721

SN - 0960-9776

VL - 71

SP - 13

EP - 21

JO - Breast

JF - Breast

ER -

Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this